IL17A and rheumatoid arthritis: For instance, IGU can inhibit interleukin (IL)-6 or IL-8 in RA synovial fibroblast-like cells via interference with nuclear factor (NF)-κB [17,18], IL-17-mediated signaling by disrupting Act1 or migration inhibitory factor (MIF) [19], and regulation of B cell differentiation by disrupting the protein kinase C (PKC) pathway [20].